Skip to main content

Displaying 61 - 70 of 282

Novel Gastrointestinal Cancer Markers in Tissue and Biofluids

Gastrointestinal

Gastrointestinal
N/A
Beauchamp, Robert
NCT00899626
VICCGI0283

Prospective, Randomized, Crossover Trial Comparing Recombinant von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women with von Willebrand Disease: The VWD Minimize Study

Multiple Cancer Types

Gynecologic, Hematologic
III
Wheeler, Allison
NCT02606045
VICCNCBH1961

Navigation Endoscopy for the Diagnosis of Indeterminate Lung Nodules, VERITAS Study

Lung

This trial studies how well navigation endoscopy works in diagnosing indeterminate lung nodules. Navigation bronchoscopy is a procedure using technology designed to guide a flexible bronchoscope (a small tube with a camera) through the natural airway route (wind-pipe and bronchi) to access the nodule. Navigation bronchoscopy may be more accurate than the standard computed tomography (CT)-guided biopsy in diagnosing patients with indeterminate lung nodules.
Lung
N/A
Maldonado, Fabien
NCT04250194
VICCTHO19102

Disposable Perfusion Phantom for Accurate DCE-MRI Measurement of Pancreatic Cancer Therapy Response

Pancreatic

This trial tests the use of a disposable perfusion phantom (P4) to decrease errors in calculating the blood flow of a tissue with DCE-MRI. DCE-MRI is used calculate blood flow of various tissues including tumors. Blood flow often serves as a critical indicator showing a disease status. For example, a pancreatic tumor has typically low blood flow, so it can be used as an indicator to identify the presence of a pancreatic tumor. In addition, an effective therapy may result in the increase of blood flow in a pancreatic tumor during the early period of treatment. Therefore, DCE-MRI may be used to determine whether the undergoing therapy is effective or not by measuring the change of blood flow in the pancreatic tumor and may help doctors decide whether to continue the therapy or try a different one. Unfortunately, the measurement of blood flow using DCE-MRI is not accurate. The use of an artificial tissue, named "phantom" or P4, together with a patient may help to reduce errors in DCE-MRI because errors will affect the images of both the patient and the phantom. Because it is known how the blood flow of the phantom appears when no errors are present, the phantom may be used to detect what kinds of errors are present in the image, how many errors are present in the image, and how to remove errors from the image.
Pancreatic
N/A
Xu, Junzhong
NCT04588025
VICCGI2099

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Ovarian

This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Ovarian
N/A
Brown, Alaina
NCT04251052
NRGGYNCC008

Neuroblastoma Maintenance Therapy Trial

Multiple Cancer Types

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg / m2 250 mg / m2 BID (strata 1, 2, 3, and 4) OR 2500 mg / m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Endocrine, Neuroblastoma (Pediatrics), Neuroendocrine, Pediatrics
II
Pastakia, Devang
NCT02679144
VICCPED16157

Fluid Measurements and MRI in Determining Biomarkers of Lymphatic Dysfunction in Patients with Breast Cancer

Breast

This trial uses fluid measurements of the arm and MRI to determine biomarkers of lymphatic dysfunction in patients with breast cancer. Studying the lymphatic system (the part of your body that helps to process and clear waste products) in different ways will help doctors understand more about lymphedema (excess fluid after lymph nodes are removed) and help with prevention and management of lymphedema in patients with breast cancer.
Breast
N/A
Donahue, Manus
NCT03760744
VICCBRE18156

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Multiple Cancer Types

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and / or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Lymphoma, Miscellaneous, Pediatric Solid Tumors
N/A
Borinstein, Scott
NCT03155620
COGAPEC1621SC

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Breast

This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
Breast
III
Raybon, Courtney
NCT03233191
ECOGBREEA1151

Artificial Tears for the Reduction of Radioiodine Levels in the Nasolacrimal Duct System of Patients with Thyroid Carcinoma following Radioiodine Therapy

Thyroid

This phase II trial studies how well artificial tears works in reducing radioiodine levels in the nasolacrimal duct system in patients with thyroid carcinoma following radioiodine therapy. Radioactive iodine therapy for thyroid carcinoma has been associated with nasolacrimal duct obstruction. Artificial tears may dilute the amount of radioactive iodine in the tears of the eyes, thus decreasing uptake by the cells lining the nasolacrimal duct system.
Thyroid
II
Sobel, Rachel
NCT04327999
VICCHN2018